Cat. No. | Product name | CAS No. |
DC2710 |
Abiraterone (CB-7598)
Abiraterone (CB-7598) is a potent CYP17 inhibitor with IC50 of 2 nM. |
154229-19-3 |
DC4127 |
ABT-263 (Navitoclax)
Featured
ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤ 1 nM, respectively. |
923564-51-6 |
DC9706 |
ABT-639
Featured
ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50 = 2 μM) and attenuates LVA currents in rat DRG neurons (IC50 = 8 μM). |
1235560-28-7 |
DC1022 |
ABT-737
Featured
ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM, respectively. |
852808-04-9 |
DC7353 |
ABT-751(E 7010)
Featured
ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μM in neuroblastoma and non-neuroblastoma cell lines, respectively. |
141430-65-1 |
DC4231 |
Linifanib (ABT-869)
Featured
ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families. |
796967-16-3 |
DC11155 |
ABX-1431
Featured
ABX-1431 (ABX1431) is a highly potent, selective, orally available, CNS-penetrant monoacylglycerol lipase (MGLL) with IC50 of 14 nM (hMGLL). |
1446817-84-0 |
DC11183 |
ABX-1431 hydrochloride
Featured
ABX-1431 (ABX1431) is a highly potent, selective, orally available, CNS-penetrant monoacylglycerol lipase (MGLL) with IC50 of 14 nM (hMGLL). |
2043074-64-0 |
DC9660 |
Acalabrutinib(ACP196)
Featured
Acalabrutinib (ACP-196) is a second-generation, selective, irreversible inhibitor of BTK. |
1420477-60-6 |
DC8760 |
Acalisib
Featured
Acalisib (GS-9820) is a potent and selective inhibitor of PI3Kδ with IC50 value of 12.7 nM. |
870281-34-8 |
DC9986 |
Acebilustat(ZK322)
Featured
Acebilustat(ZK322) is a potent and selective leukotriene A4 hydrolase inhibitor. |
943764-99-6 |
DC10318 |
Acelarin
Featured
Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine. |
840506-29-8 |
DC9900 |
Acetaminophen
Featured
Acetaminophen is a COX inhibitor for COX-1 and COX-2 with IC50 of 113.7 μM and 25.8 μM, respectively. |
103-90-2 |
DC11512 |
Acrizanib
Featured
Acrizanib(LHA510) is a potent and selective angiogenesis inhibitor and VEGFR‑2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. |
1229453-99-9 |
DC11439 |
Nemorexant
Featured
ACT-541468 is a dual orexin receptor antagonist. |
1505484-82-1 |
DC10417 |
Acumapimod (BCT197)
Featured
Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC50 of less than 1 μM for p38α. |
836683-15-9 |
DC8476 |
ACY-738
Featured
ACY-738 demonstrates inhibitory activity against recombinant HDAC6 with IC50 values of 1.7 nM, with respective average selectivity over class I HDACs being 100-fold. |
1375465-91-0 |
DCAPI1273 |
Acyclovir (Aciclovir)
Acyclovir (Aciclovir) |
59277-89-3 |
DC11886 |
Adavivint
Featured
Adavivint (SM-04690, SM 04690, SM04690) is a novel small molecule Wnt pathway inhibitor with EC50 of 3 nM in vitro |
1467093-03-3 |
DC7050 |
ADL5859 HCl
Featured
ADL5859 agonizes δ-opioid receptor with a 1000-fold selectivity than µ- or κ-opioid receptor with Ki of 32 nM and 37 nM, respectively.ADL5859 displays weak inhibitory activity at the hERG channel with an IC50 of 78 μM. The EC50 of ADL5859 against δ opioid |
850173-95-4 |
DC11097 |
ADX-102 (Reproxalap;NS-2)
Featured
ADX-102 (Reproxalap, NS-2) is a novel small molecule immunomodulator that covalently binds aldehydes including malondialdehyde and 4-hydroxynonenal, which have been shown to mediate inflammatory pain; DX-102 is a promising agent for the treatment of dry eye disease. |
916056-79-6 |
DC5113 |
AEE-788 (NVP-AEE788)
Featured
AEE788 is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2. |
497839-62-0 |